Synopsis: The healthcare stocks jumped nearly 7% on the news that there could be up to 10% selling of promoter stakes, which attracted investors due to the anticipated institutional involvement.
The share of this company, which operates across both Human and Animal Health sectors, specializing in Active Pharmaceutical Ingredients, advanced intermediates, and Finished Drug Formulations, after speculation of promoter selling stake.
With a market capitalization of Rs 11,852 crore, Viyash Scientific Ltd’s share on Monday made a day high of Rs 305.45 per share, up by 6.9 percent up from its previous day’s close price of Rs 254.55 per share. The share of this company gave a return of 47 percent over the last year.
What Happened
According to sources, the current plan of Carlyle is to sell off a 10 percent stake in Sequent Scientific Company, where the company holds the position of promoter with a 61.3 percent stake in the company. This stake sale has been attributed to its investment in Viyash Scientific, which got consolidated with Sequent Scientific, according to reports.
Earlier, the promoter’s stake increased from 53 percent to 61.3 percent through CA Harbor Investments and CA Hull Investments. The stake sale seems to be attracting attention from mutual fund houses and strategic investors.
As of Q4 FY26, the equity structure has changed in the company’s ownership. The ownership by the promoter rose to 61.31 percent from 52.61 percent the previous year. FIIs lowered their share to 2.94 percent in Q4 of FY26 from 6.05 percent in Q4 of FY25. In comparison, DIIs decreased to 7.98 percent from 12.82 percent in the previous period. The public holding is 27.67 percent, which is marginally lower than 28.36 percent, while other category holdings amount to 0.09 percent.
About the Company
Viyash Scientific Ltd. (formerly known as Sequent Scientific Limited) is a fully backward-integrated, global pharmaceutical enterprise headquartered in Hyderabad, India. It operates across both Human and Animal Health sectors, specializing in Active Pharmaceutical Ingredients (APIs), advanced intermediates, and Finished Drug Formulations (FDFs).
Financial Highlight: The revenue from operations grew by 129 percent to Rs 920 crore in Q4 FY26 from Rs 402 crore in Q4 FY25, and EBIDT grew by 298 percent to Rs 184 crore in Q4 FY26 from Rs 46.2 crore in Q4 FY25. This was accompanied by a net profit growth of 455 percent to Rs 66.4 crore in Q4 FY26 from Rs 10.4 crore in Q4 FY25, resulting in an EPS growth of 222 percent to Rs 1.19 per share in Q4 FY26 from Rs 0.37 per share in Q4 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
